Background: Attenuated measles virus (MV) strains are promising agents currently being tested against solid tumors or hematologic malignancies in ongoing phase I and II clinical trials; factors determining oncolytic virotherapy success remain poorly understood, however. Methods: We performed RNA sequencing and gene set enrichment analysis to identify pathways differentially activated in MV-resistant (n ¼ 3) and -permissive (n ¼ 2) tumors derived from resected human glioblastoma (GBM) specimens and propagated as xenografts (PDX). Using a unique gene signature we identified, we generated a diagonal linear discriminant analysis (DLDA) classification algorithm to predict MV responders and nonresponders, which was validated in additional randomly selected GBM and ovarian cancer PDX and 10 GBM patients treated with MV in a phase I trial. GBM PDX lines were also treated with the US Food and Drug Administration-approved JAK inhibitor, ruxolitinib, for 48 hours prior to MV infection and virus production, STAT1/3 signaling and interferon stimulated gene expression was assessed. All statistical tests were two-sided. Results: Constitutive interferon pathway activation, as reflected in the DLDA algorithm, was identified as the key determinant for MV replication, independent of virus receptor expression, in MV-permissive and -resistant GBM PDXs. Using these lines as the training data for the DLDA algorithm, we confirmed the accuracy of our algorithm in predicting MV response in randomly selected GBM PDX ovarian cancer PDXs. Using the DLDA prediction algorithm, we demonstrate that virus replication in patient tumors is inversely correlated with expression of this resistance gene signature (q ¼ -0.717, P ¼ .03). In vitro inhibition of the interferon response pathway with the JAK inhibitor ruxolitinib was able to overcome resistance and increase virus production (1000-fold, P ¼ .03) in GBM PDX lines. Conclusions: These findings document a key mechanism of tumor resistance to oncolytic MV therapy and describe for the first time the development of a prediction algorithm to preselect for oncolytic treatment or combinatorial strategies.
Oncolytic virotherapy relies on virus replication within tumor cells to mediate direct cell killing of tumor cells and/or activation of antitumor immunity. Although individual cases of patients benefiting from oncolytic virotherapy have been documented and one immuno-virotherapy product recently received regulatory approval, success and preclinical promise have not always been reproducible (1) (2) (3) . There is an urgent need to identify factors beyond virus receptor expression that are involved in restriction of viral replication in treated tumors of individual patients.
Attenuated measles virus (MV) strains of the Edmonston vaccine lineage enter cells through three known receptors: CD46, SLAM, and Nectin-4 (4-7). MV represents an appealing oncolytic platform due to the tumor selectivity, bystander killing effect, amenability to genetic engineering, and the excellent safety record observed in several clinical trials (8) . Ongoing clinical trials utilize MV derivatives for the treatment of several tumor types, such as glioblastoma (GBM; NCT00450814), multiple myeloma (NCT00450814), ovarian cancer (OvCa; NCT02364713), head and neck cancer (NCT01846091), breast cancer (NCT01846091), and mesothelioma (NCT01503177). In the context of early evidence of biological activity in these trials, we aimed to identify specific mechanisms within tumor cells that can directly restrict virus replication (1, 9, 10) .
RNA sequencing technology and the use of pharmacogenomics can provide an effective tool to identify gene variants and expression signatures that correlate with drug response and metabolism (11) (12) (13) (14) (15) . To our knowledge, such an approach has not been used to optimize efficacy in virotherapy trials. We hypothesized that oncolytic MV replication in GBM cells is determined by restriction mechanisms following viral entry. In this study, we sought to analyze predictors for replication of oncolytic MV in GBM and OvCa tumors through the use of an indepth expression analysis of differentially activated pathways between MV-permissive and -resistant primary patient-derived xenograft (PDX) lines. The goal of this study is to identify mechanisms of oncolytic MV resistance that can be used to preselect patients who are likely to respond to MV therapy and develop combinatorial strategies that can circumvent resistance.
Methods
An additional description of the methods can be found in the Supplementary Methods (available online).
MV Antitumor Effect In Vitro
GBM cells were infected at multiplicities of infection (MOIs) of 0.1 and 1.0 with MV strains diluted in Opti-MEM (Life Technologies, Carlsbad, CA). MTT proliferation assay (ATCC, Rockville, MD) was used to determine the cell viability at 24 hours to 10 days post-MV inoculation. Samples were run in triplicate wells in 96-well plates. Cells inoculated with inactivated MV were used as controls.
Patients and Patient Samples
All studies involving patients were approved by the Mayo Clinic Institutional Review Board (Mayo Clinic IRB#06-004440). Written informed consent was obtained for all patients. Patients with recurrent GBM tumors were treated by stereotactic injection of MV-CEA in an ongoing phase I clinical trial at Mayo Clinic (NCT00390299; Rochester, MN). Patients included in this analysis derived from cohort B and received intratumoral injection of the virus on day 1 via a catheter. On day 5, the tumor was resected, and a second dose was administered to the tumorinfiltrated parenchyma surrounding the resection cavity. Tumor tissue derived from 10 consecutive study patients was included in this analysis. RNA was isolated, and gene expression was analyzed from tumor tissue prior to MV therapy, described in the Supplementary Methods (available online).
Statistical Analysis
Statistical analysis was performed using Microsoft Excel, GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA), and R (16). Student t tests were utilized to test the difference in comparisons between the two groups, including virus production, MV entry as measured by green fluorescent protein (GFP), IFN-a/b production, interferon-stimulated gene (ISG) expression, and MV replication (17) . Differences in expression between the MV-resistant and MV-permissive groups were evaluated using unequal-variance t tests. P values of less than .05 were considered statistically significant. All statistical tests were two-sided.
Kaplan-Meier survival curves and log-rank tests were used to obtain median survival times and compare the survival of the animal groups treated with active or inactive MV (18) .
The GeneCodis online resource (http://genecodis.cnb.csic.es/) was utilized to perform pathway enrichment analysis between the MV-resistant group (GBM6, GBM150 and GBM39) and the MV-permissive group (GBM43 and GBM64) (19, 20) ; 19 835 genes were used as an input into GeneCodis. We used a custom script in the R programming language to combine fold-change values and P values with functional grouping of proteins (16) . Additional information is described in detail in the Supplementary Methods (available online).
Diagonal linear discriminant analysis (DLDA) was used as the tool to build a class prediction statistical model (21) . The DLDA model was generated using the 22 ISG gene panel identified in the pathway enrichment analysis. As described in Figure 2 , a comparison of MV-resistant and MV-permissive cells revealed the constitutive activation of the IFN pathway, characterized by elevated expression of 22 genes (P < .05 and foldchange > 1.5). Using this gene panel, the DLDA model yields coefficients for each gene and a constant, which can be used to generate a DLDA score for prospective samples to predict response. To accommodate expression data from multiple gene expression platforms, expression data were log2-transformed then standardized to a mean of 0.0 and standard deviation of 1.0. Additional information on the DLDA model is described in the Supplementary Methods (available online).
Pearson coefficients were obtained to evaluate the correlation between virus replication in patient samples and the DLDA scores using R (22) . Heat maps were used to visually display the standardized expression data. The colors relate to the overall range of the expression data. The dendrograms associated with each heat map show the clustering of both samples and genes based on hierarchical clustering using complete linkage with the distance metric 1 correlation between the samples or genes, respectively (23) .
Results

MV Infection in Primary GBM PDX Lines
We evaluated MV replication in MV-resistant (GBM39) and MVpermissive (GBM12) primary patient-derived GBM xenograft lines (24) . These lines are derived from resected human GBM patient tumors propagated as xenografts, and following orthotopic implantation, they have been shown to maintain the molecular characteristics and invasiveness of their human tumor of origin (25, 26) . MV production in GBM12 cells reached 6.8Â10 4 tissue culture infection dose 50% per mL (TCID 50 /mL) at 72 hours with complete destruction of the cell monolayer ( Figure 1 , A and C). In comparison, virus production in GBM39 cells was only 1.8Â10 2 TCID 50 /mL (387-fold lower infectious progeny, P < .001), with more than 47.0% (SD ¼ 3.9%) of GBM39 cells remaining alive seven days postinfection ( Figure 1, A and B) . Orthotopic in vivo models demonstrated that athymic nude mice implanted with GBM12 cells responded to MV therapy with a 37-day prolongation in median survival (194% increase). In comparison, the MV-treated GBM39 mouse group demonstrated only a six-day prolongation in median survival ( Figure 1D ). We next evaluated MV entry into the GBM cells using MV encoding a green fluorescent protein (GFP) reporter (27) . MV enters GBM12 and GBM39 cells with a similar efficiency (mean repeated two or more times. A two-sided Student t test was used to determine statistically significant differences. Kaplan-Meier survival curves and log-rank tests were used to obtain median survival times and compare survival between animal groups. Data are presented as the mean and standard deviation (A-C, E, G, and H). 
Constitutive Type I Interferon Pathway Activation in MV-Resistant GBM Cells
We performed RNA-Seq analysis using RNA isolated from athymic mice orthotopically implanted with 41 primary orthotopic GBM models. Expression data for GBM12 were excluded from this analysis due to poor RNA quality and low gene coverage. From this analysis, we identified four additional permissive and resistant GBM models deriving from human patients. GBM43 and GBM64 cells supported MV replication (>2.0Â10 4 TCID 50 / mL), whereas replication in GBM6 and GBM150 cells was statistically significantly lower (<1.6Â10 3 TCID 50 /mL, P < .05) (Figure 2A ; Supplementary Table 2 , available online). In line with these differences in MV replication, 100% of GBM43 and GBM64 cells were effectively killed upon MV infection, whereas 42.5% (SD ¼ 4.7%) and 34.3% (SD ¼ 1.2%) of GBM6 and GBM150 cells survived seven days postinfection, respectively ( Figure 2B -E). Using expression data from these lines, we performed gene set enrichment analysis to identify differential pathway activation between the resistant (GBM39, 6, and 150) and permissive lines (GBM43 and 64). Constitutive activation of the type I Interferon pathway in the resistant group was the second most differentially activated pathway (P ¼ 2.14Â10 -20 ) ( Figure 2F ;
Supplementary Table 3 , available online). We focused on the type I interferon pathway due to the known antiviral functions of this pathway (29) . Twenty-two genes involved in the interferon pathway are differentially expressed (fold-change > 1.5, P < .05 for all) between the resistant and permissive groups and were used as the gene signature. Activation of the IFN pathway remains an important difference between MV-resistant and -permissive cells also when using more stringent criteria (fold-change > 2, P < .05 for all) (Supplementary Table 3 , available online).
IFN Activation as a Predictive Marker for Response to Oncolytic MV Therapy
The diagonal linear discriminant analysis (DLDA) class prediction algorithm was generated using the 22 gene signature (13 Figure 3A ). Of the 35 primary GBM PDX lines tested, 18 were predicted to be responders. MV production in a randomly selected line assigned to the responders (GBM10) reached high levels of virus production (1.4Â10
5 TCID 50 /mL), whereas MV production in another randomly selected line designated as a nonresponder (GBM76) only reached 2.2Â10 3 TCID 50 /mL at 72 hours ( Figure 3B ).
In line with the decreased virus production, cell killing was statisitically significantly impaired in the resistant line relative to the predicted responder ( Figure 3, C (Figure 3 , E and F). Similar analysis and DLDA predictions were generated for 86 OvCa PDXs ( Figure 3G ; Supplementary Table 6, available online). SCID beige mice implanted with a randomly selected responder (PH077) resulted in a statistically significant 22-day prolongation in median survival for inactivated MV vs MV therapy groups (16 vs 38 days, respectively, HR ¼ 7.49, 95% CI ¼ 1.62 to 34.54, P ¼ .01). In comparison, SCID beige mice implanted with the randomly selected nonresponder (PH080) had no benefit from MV therapy, as compared with inactivated virus (41 vs 39 days, respectively, HR ¼ 1.58, 95% CI ¼ 0.45 to 5.55, P ¼ .48) (Figure 3, H and I ).
ISG Expression in MV-Treated GBM Patients
To further validate constitutive IFN activation as an indicator for response to MV therapy, we examined tumors of GBM patients treated with MV in an ongoing phase I clinical trial (NCT00390299). Virus replication in treated patients was analyzed five days post-therapy in the first 10 patients consecutively treated in arm B of the trial and ranged from nondetectable to 6.0Â10 7 genome copies/mg RNA ( Figure 4A ).
Gene expression was measured in the 10 MV-treated patients using a custom Nanostring gene panel (Supplementary  Table 7 , available online). Expression of the MV entry receptors was similar among the 10 treated patients, suggesting a mechanism of postentry restriction ( Figure 4B ). Utilizing gene expression of the 22 gene signature, we applied the DLDA scoring system in 10 consecutive GBM patients treated in arm B of the study (NCT00390299) ( Figure 4C ; Supplementary Table 8, available online). An increase in the DLDA score (elevated ISG expression) was inversely correlated with the virus replication measured in the patient's tumor (q ¼ -0.717, P ¼ .03) ( Figure 4D ). The patient with the highest DLDA score (greater than 150) had no detectable viral replication in the tumor, whereas the two patients with the lowest DLDA scores (less than -250) had the highest level of viral replication (6.8Â10 6 
Effects of JAK1/2 Inhibition in MV-Resistant GBM Lines
Upon viral infection, the host antiviral defense mechanism triggers IFN production and signaling through JAK1/Tyk2 to activate STAT1/2, which associates with IRF9 to form the ISGF3 complex that activates ISG expression (30) . Therefore, we explored the use of pharmacological agents to overcome resistance through inhibition of the JAK/STAT signaling pathway with the US Food and Drug Administration (FDA)-approved JAK1/2 inhibitor ruxolitinib (Jakafi). Virus production was statistically significantly increased at 48 hours postinfection and nearly 1000-fold greater by 96 hours in Jakafi-treated cells (P ¼ .03) ( Figure 5A ). The increased virus production and spread also led to increased cell killing in Jakafi-pretreated cells relative to control-treated cells ( Figure 5B ; Supplementary Table 2 Relative to control-treated cells, expression of ISGs, such as RSAD2, OAS2, MX1, MX2, and SAMD9, were statistically significantly decreased in Jakafi-treated cells (Figure 5, C-G) . Furthermore, pretreatment with Jakafi blocked ISG induction upon MV infection (MOI 5), whereas ISG expression was statistically significantly increased upon infection in the controltreated cells.
We next investigated the signaling molecules involved in mediating ISG expression. Interestingly, STAT3 is constitutively activated in the uninfected cells, whereas activated STAT1 was not detected. Phosphorylation of both STAT1 and STAT3 was induced by four hours postinfection; however, this process was inhibited in the presence of Jakafi ( Figure 5I ). In MV replicationpermissive cells, a similar response was observed, but it peaked eight to 12 hours postinfection ( Figure 5J ; Supplementary Figure  4 , available online). We next investigated the timing of JAK/ STAT signaling inhibition that would be required to reverse restriction. Jakafi administered up to 12 hours postinfection is sufficient to restore MV production to levels similar to a full course of Jakafi treatment ( Figure 5H ), suggesting that inhibition of the antiviral response is critical for propagating infection in resistant lines. Additionally, we challenged resistant cells with a recombinant MV encoding the wild-type phosphoprotein (MV-GFP-P wt ). The phosphoprotein gene of wild-type MV encodes the P/V/C 
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proteins and plays an important role in inhibiting IFN induction and signaling (31) (32) (33) . Infection with MV-GFP-P wt leads to a statistically significant decrease in ISG induction relative to infection with MV-GFP (P ¼ .02) and successfully replicates in resistant GBM39 cells (Supplementary Figure 3 , B and C, and Supplementary Table 2 , available online). These results 
highlight the importance of utilizing the basal ISG expression profile as a reliable indicator for responsiveness to MV therapy.
Discussion
Although the interferon pathway is an effective defense mechanism against viral infection, tumor cells are frequently defective in this pathway. Differential activation of the IFN signaling pathway has been employed as an argument supporting tumor selectivity of oncolytic viruses (34) (35) (36) . The impetus of the work presented in this manuscript was the observation that despite adequate levels of virus receptor expression enabling viral entry, there was variability in MV replication, permissiveness, and antitumor effect in patient-derived xenografts. An association between constitutive interferon activation and reduced infection was observed in GBM and OvCa PDXs. We report for the first time the development of a DLDA algorithm to predict permissiveness to viral replication in human tumors. Chemical inhibition of JAK1/2, a critical component of ISG signaling, which can reverse the primed state and/or the antiviral response upon infection, sensitized virus-resistant cells to MV infection, further supporting our conclusions. These results have several clinical implications for oncolytic virotherapy. First, a defective IFN system in tumor cells is one of the main arguments for the use of oncolytic viruses to selectively target tumor cells (34, 37, 38) . Our data demonstrate innate variations in interferon response antiviral defense mechanisms within tumors that can have a statistically and biologically significant impact on MV replication. Importantly, several of the ISGs identified are known to restrict other oncolytic viruses currently being tested, such as vesicular stomatitis virus, HSV-1, Vaccinia, and Newcastle Disease Virus (39) (40) (41) (42) (43) (44) (45) . Second, our DLDA scoring-based algorithm identified three tiers of GBM patients: low scores (<-250) identified patients with tumors extremely permissive to MV replication, and high scores (>150) correlated with MV-resistant tumors, while a third class of patients who had moderate DLDA scores (-250 to þ150) had intermediate levels of virus replication. The level of replication reached in these patients would still be adequate to allow them to benefit from the immunostimulatory potential of oncolytic cell death, however. Thus, these patients could be excellent candidates for combinatorial strategies, for example, using the FDA-approved JAK1/2 inhibitor ruxolitinib, checkpoint inhibitors, such as monoclonal antibodies targeting CTLA-4 and PD-L1, or recombinant MV strains encoding immunomodulatory genes (46) (47) (48) (49) (50) . We and others have recently demonstrated that even low levels of oncolytic viral replication are adequate for the synergistic effect of virotherapy with anti-PD1 inhibition to be materialized (50) . A schematic proposal of how this algorithm could be applied for optimal patient selection in clinical trials is provided as Supplementary Figure 5 (available online).
While our study is able to validate the predictive capabilities of our classification system, according to ISG expression, our validation in patients is limited by the number of GBM patients who have been treated with oncolytic MV. We are in the process of validating these results in additional GBM and ovarian cancer patients treated with MV strains in other clinical trials (3), as well as prospectively utilizing the DLDA algorithm we developed to enrich measles virotherapy trials for patients likely to respond. Additional mechanistic studies are planned to characterize the specific role of JAK1 vs JAK2 inhibition on MV infection response and develop clinical combinatorial strategies.
Our results represent the first successful effort to associate tumor molecular characteristics with viral replication in PDXs and clinical trial patients alike. A recently reported trial attempted to identify predictors of response to oncolytic virotherapy in patient samples (51) . The identified survival-related neuronal subtype signature appeared to be prognostic rather than predictive because it lacked the mechanistic rationale that could explain an association with virotherapy effect; it was not shown to be associated with viral replication and could not predict outcome at the individual patient level. In our study, we developed a unique scoring system that was able to accurately predict the extent of viral replication at the individual patient level. The data were validated in ovarian and GBM avatars; therefore, our algorithm is predictive across multiple tumor types. Additionally, given the role of ISGs in determining replication across many different oncolytic platforms, this predictive gene signature could have broad translational and clinical implications for the field of oncolytic virotherapy (39) (40) (41) (42) (43) (44) (45) .
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